Cargando…
Transcutaneous Electrical Acupoint Stimulation for Moderate to Severe Pain in Hepatocellular Carcinoma: A Protocol for a Randomized Controlled Trial
BACKGROUND: Cancer-related pain is one of the primary symptoms of patients with hepatocellular carcinoma (HCC). Previous studies have shown that transcutaneous electrical acupoint stimulation (TEAS) is effective in treating patients with acute or chronic pain. In China, it is indispensable to evalua...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271907/ https://www.ncbi.nlm.nih.gov/pubmed/35832212 http://dx.doi.org/10.2147/JPR.S361821 |
_version_ | 1784744777056518144 |
---|---|
author | Wu, Pin Zhu, Lu Zheng, Shi-Yu Li, Jun-Xiong Wu, Meng-Die Wang, Wen-Jia Hou, Yu-Chao Li, Jing Wu, Huan-Gan |
author_facet | Wu, Pin Zhu, Lu Zheng, Shi-Yu Li, Jun-Xiong Wu, Meng-Die Wang, Wen-Jia Hou, Yu-Chao Li, Jing Wu, Huan-Gan |
author_sort | Wu, Pin |
collection | PubMed |
description | BACKGROUND: Cancer-related pain is one of the primary symptoms of patients with hepatocellular carcinoma (HCC). Previous studies have shown that transcutaneous electrical acupoint stimulation (TEAS) is effective in treating patients with acute or chronic pain. In China, it is indispensable to evaluate the efficacy of TEAS in combination with opioids for the treatment of moderate to severe HCC-related pain. METHODS/DESIGN: This is a single-center clinical, prospective randomized controlled clinical trial protocol. 104 patients will be randomly divided into the observation group and the control group in a ratio of 1:1.In addition to routine cancer pain medication, the two groups of patients will receive TEAS treatment twice a day for one week. Acupoints will include bilateral Hegu(LI4), Neiguan(PC6), Zusanli(ST36), Taichong(LR3), Ganshu(BL18), Geshu(BL17), Qimen(LR14), and Zhangmen(LR13). The treatment time is from 9:00 a.m. to 11:00 p.m. and from 4:00 p.m. to 6:00 p.m. The primary outcome measures are the Numerical Rating Scale (NRS) and the secondary outcome measures include the Brief Pain Inventory(BPI), dosage and administration duration of opioid drugs, frequency of nausea, vomiting and defecation, Karnofsky Performance Status Scale (KPS), Quality of life scale (QOL), Brief Fatigue Inventory (BFI). The outcome measures will be evaluated at baseline, during treatment and 1 week after treatment. DISCUSSION: Results of this trial are expected to clarify the value of TEAS stimulation performed on specific points in the management of moderate to severe pain in HCC. TRIAL REGISTRATION: Chinese clinical trial registry, ChiCTR2100044615 (http://www.chictr.org.cn), Registered on 24 March 2021. |
format | Online Article Text |
id | pubmed-9271907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-92719072022-07-12 Transcutaneous Electrical Acupoint Stimulation for Moderate to Severe Pain in Hepatocellular Carcinoma: A Protocol for a Randomized Controlled Trial Wu, Pin Zhu, Lu Zheng, Shi-Yu Li, Jun-Xiong Wu, Meng-Die Wang, Wen-Jia Hou, Yu-Chao Li, Jing Wu, Huan-Gan J Pain Res Study Protocol BACKGROUND: Cancer-related pain is one of the primary symptoms of patients with hepatocellular carcinoma (HCC). Previous studies have shown that transcutaneous electrical acupoint stimulation (TEAS) is effective in treating patients with acute or chronic pain. In China, it is indispensable to evaluate the efficacy of TEAS in combination with opioids for the treatment of moderate to severe HCC-related pain. METHODS/DESIGN: This is a single-center clinical, prospective randomized controlled clinical trial protocol. 104 patients will be randomly divided into the observation group and the control group in a ratio of 1:1.In addition to routine cancer pain medication, the two groups of patients will receive TEAS treatment twice a day for one week. Acupoints will include bilateral Hegu(LI4), Neiguan(PC6), Zusanli(ST36), Taichong(LR3), Ganshu(BL18), Geshu(BL17), Qimen(LR14), and Zhangmen(LR13). The treatment time is from 9:00 a.m. to 11:00 p.m. and from 4:00 p.m. to 6:00 p.m. The primary outcome measures are the Numerical Rating Scale (NRS) and the secondary outcome measures include the Brief Pain Inventory(BPI), dosage and administration duration of opioid drugs, frequency of nausea, vomiting and defecation, Karnofsky Performance Status Scale (KPS), Quality of life scale (QOL), Brief Fatigue Inventory (BFI). The outcome measures will be evaluated at baseline, during treatment and 1 week after treatment. DISCUSSION: Results of this trial are expected to clarify the value of TEAS stimulation performed on specific points in the management of moderate to severe pain in HCC. TRIAL REGISTRATION: Chinese clinical trial registry, ChiCTR2100044615 (http://www.chictr.org.cn), Registered on 24 March 2021. Dove 2022-07-06 /pmc/articles/PMC9271907/ /pubmed/35832212 http://dx.doi.org/10.2147/JPR.S361821 Text en © 2022 Wu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Study Protocol Wu, Pin Zhu, Lu Zheng, Shi-Yu Li, Jun-Xiong Wu, Meng-Die Wang, Wen-Jia Hou, Yu-Chao Li, Jing Wu, Huan-Gan Transcutaneous Electrical Acupoint Stimulation for Moderate to Severe Pain in Hepatocellular Carcinoma: A Protocol for a Randomized Controlled Trial |
title | Transcutaneous Electrical Acupoint Stimulation for Moderate to Severe Pain in Hepatocellular Carcinoma: A Protocol for a Randomized Controlled Trial |
title_full | Transcutaneous Electrical Acupoint Stimulation for Moderate to Severe Pain in Hepatocellular Carcinoma: A Protocol for a Randomized Controlled Trial |
title_fullStr | Transcutaneous Electrical Acupoint Stimulation for Moderate to Severe Pain in Hepatocellular Carcinoma: A Protocol for a Randomized Controlled Trial |
title_full_unstemmed | Transcutaneous Electrical Acupoint Stimulation for Moderate to Severe Pain in Hepatocellular Carcinoma: A Protocol for a Randomized Controlled Trial |
title_short | Transcutaneous Electrical Acupoint Stimulation for Moderate to Severe Pain in Hepatocellular Carcinoma: A Protocol for a Randomized Controlled Trial |
title_sort | transcutaneous electrical acupoint stimulation for moderate to severe pain in hepatocellular carcinoma: a protocol for a randomized controlled trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271907/ https://www.ncbi.nlm.nih.gov/pubmed/35832212 http://dx.doi.org/10.2147/JPR.S361821 |
work_keys_str_mv | AT wupin transcutaneouselectricalacupointstimulationformoderatetoseverepaininhepatocellularcarcinomaaprotocolforarandomizedcontrolledtrial AT zhulu transcutaneouselectricalacupointstimulationformoderatetoseverepaininhepatocellularcarcinomaaprotocolforarandomizedcontrolledtrial AT zhengshiyu transcutaneouselectricalacupointstimulationformoderatetoseverepaininhepatocellularcarcinomaaprotocolforarandomizedcontrolledtrial AT lijunxiong transcutaneouselectricalacupointstimulationformoderatetoseverepaininhepatocellularcarcinomaaprotocolforarandomizedcontrolledtrial AT wumengdie transcutaneouselectricalacupointstimulationformoderatetoseverepaininhepatocellularcarcinomaaprotocolforarandomizedcontrolledtrial AT wangwenjia transcutaneouselectricalacupointstimulationformoderatetoseverepaininhepatocellularcarcinomaaprotocolforarandomizedcontrolledtrial AT houyuchao transcutaneouselectricalacupointstimulationformoderatetoseverepaininhepatocellularcarcinomaaprotocolforarandomizedcontrolledtrial AT lijing transcutaneouselectricalacupointstimulationformoderatetoseverepaininhepatocellularcarcinomaaprotocolforarandomizedcontrolledtrial AT wuhuangan transcutaneouselectricalacupointstimulationformoderatetoseverepaininhepatocellularcarcinomaaprotocolforarandomizedcontrolledtrial |